To review non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
Women with a gBRCA1 or 2 mutations face a high cumulative breast and ovarian cancer risk. While bilateral mastectomy (PBM) and bilateral salpingo-oophrectomy (PBSO) profoundly reduce the respective cancer risks, they are also associated with considerable side effects. There is therefore an urgent need for alternative and non-surgical risk reduction options. Tamoxifen and aromatase inhibitors have both been evaluated in secondary prevention, but their benefit in primary prevention is currently unknown in BRCA mutation carriers. In addition, their use is compromised by their side effect profile which makes them less appealing for a use in chemoprevention.
Summary and outlook
Denosumab is a well-tolerated osteoprotective drug, which has been demonstrated to have a potential preventive effect particularly in BRCA1-deficient models in vitro. The prospectively randomized double-blind BRCA-P trial is currently investigating the preventative effect of denosumab in healthy BRCA1 germ line mutation carriers.
Research funding: None declared.
Conflict of interest: None declared.
Informed consent: Not applicable.
Ethical approval: Not applicable.
1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017;317:2402–16. https://doi.org/10.1016/j.ejso.2009.07.175. Search in Google Scholar
2. Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, Sacchini V, et al. Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. Breast 2017;34:S82–4. https://doi.org/10.1016/j.breast.2017.06.034. Search in Google Scholar
3. Visvanathan K1, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235–58. https://doi.org/10.1200/JCO.2008.20.5179. Epub 2009 May 26. Search in Google Scholar
4. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251–6. https://doi.org/10.1017/s147090310600931x. Search in Google Scholar
5. Phillips KA, and Lindeman GJ. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?. Future Oncol 2014;10:499–502. https://doi.org/10.2217/fon.13.278. Search in Google Scholar
6. Phillips KA1, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013;31:3091–9. Search in Google Scholar
7. Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK. Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) 2017;12:15–9. https://doi.org/10.1159/000455999. Search in Google Scholar
8. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. science 2006;314:1467–70. https://doi.org/10.3410/f.1057879.517859. Search in Google Scholar
9. Pujol P1, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, et al. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer 2012;11:77–84. https://doi.org/10.1158/0008-5472.sabcs11-ot2-04-03. Search in Google Scholar
11. Kim J, Oktay K. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control 2013;24:421–6. https://doi.org/10.1007/s10552-012-0127-3. Search in Google Scholar
12. Lee HJ, Gallego-Ortega D, Ledger A, Schramek D, Joshi P, Szwarc MM, et al. Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development 2013;140:1397–401. https://doi.org/10.1242/dev.088948. Search in Google Scholar
13. Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, et al. RANKL/RANK control Brca1 mutation. Cell Res 2016;26:761–74. Search in Google Scholar
14. Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, et al. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ. Nat Med 2016;22:933–9. Search in Google Scholar
15. von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat Rev 2019;76:57–67. https://doi.org/10.1016/j.ctrv.2019.05.003. Search in Google Scholar
16. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082–92. https://doi.org/10.1016/j.ejca.2012.08.002. Search in Google Scholar
17. Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:339–51. https://doi.org/10.1017/s1470903109123453. Search in Google Scholar
© 2020 Walter de Gruyter GmbH, Berlin/Boston